EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

4.27.2022

Download

EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

- First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated Stage IV non-small cell lung cancer (NSCLC)
- Oral presentation featuring the primary analysis from Phase 2 GEMSTONE-201 study of sugemalimab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (ENKTL), a rare and aggressive form of Non-Hodgkin lymphoma
- Initial presentation on the activity of aumolertinib in patients with central nervous system (CNS) metastases from Phase 3 AENEAS study in advanced EGFR-mutated NSCLC

CAMBRIDGE, Mass. – April 27, 2022 – EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that new data on its lead oncology programs will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022.

Presentations at ASCO will feature updated data on the investigational PD-L1 inhibitor sugemalimab from the GEMSTONE-302 (NCT03789604) and GEMSTONE-201 (NCT03595657) trials as initial systemic treatment for patients with Stage IV NSCLC and as treatment for patients with relapsed or refractory ENKTL, respectively. Data will also be presented on the activity of the investigational EGFR-tyrosine kinase inhibitor (TKI) aumolertinib from the Phase 3 AENEAS trial (NCT03849768) in patients with advanced EGFR-mutated NSCLC and CNS metastases.

Overview of presentations featuring EQRx oncology programs

Investigational Program	Abstract Title	Presentation Details
Sugemalimab	A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based	Abstract #9027, poster presentation

	chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non-small cell lung cancer (NSCLC)[1]	Session: Lung Cancer – Non-Small Cell Metastatic DATE: Monday, June 6, 2022 TIME: 9:00 a.m. – 12:00 p.m. ET Abstract #7501, oral presentation
Sugemalimab	GEMSTONE-201: Pre-planned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL)) [1]	Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia DATE: Friday, June 3, 2022 TIME: 2:00 p.m. – 5:00 p.m. ET
Aumolertinib	Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS)[2]	Abstract #9096, poster Session: Lung Cancer – Non-Small Cell Metastatic DATE: Monday, June 6, 2022

TIME: 9:00 a.m. –
12:00 p.m. ET

About Sugemalimab
Sugemalimab is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) that is currently being investigated in several ongoing clinical trials, including studies in relapsed or refractory extranodal natural killer/T cell lymphoma (ENKTL), Stage III non-small cell lung cancer (NSCLC), Stage IV NSCLC, gastric cancer and esophageal cancer. In October of 2020, the U.S. Food and Drug Administration (FDA) granted sugemalimab Breakthrough Therapy Designation for the treatment of adult patients with relapsed or refractory ENKTL. Sugemalimab in combination with chemotherapy is approved by the National Medical Products Administration (NMPA) of China for the first-line treatment of patients with metastatic squamous and non-squamous NSCLC. EQRx has partnered with CStone Pharmaceuticals on global development of sugemalimab with the goal of expanding access worldwide. EQRx holds the development and commercialization rights to sugemalimab outside of Greater China.

About Aumolertinib
Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR. Aumolertinib is being investigated in several ongoing clinical trials, including studies in first- and second-line EGFR-mutated non-small cell lung cancer (NSCLC). Aumolertinib is approved by the National Medical Products Administration (NMPA) of China for first-line and second-line treatment of patients with locally advanced or metastatic EGFR mutation-positive NSCLC. Aumolertinib was discovered by Hansoh Pharmaceuticals, and EQRx has partnered with Hansoh Pharmaceuticals on global development of aumolertinib with the goal of expanding access worldwide. EQRx holds the development and commercialization rights to aumolertinib outside of Greater China.

About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_GLOBAL, LinkedIn, Instagram: @eqrxinc.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may be identified by the use of

words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “design,” “strategy,” “future,” “opportunity,” “continue,” “aim,” “goal,” “plan,” “may,” “look forward,” “should,” “will,” “would,” “will be,” “will likely result,” and similar expressions. These forward-looking statements include, but are not limited to, express or implied statements regarding EQRx’s ability to develop and deliver innovative medicines at radically lower prices, EQRx’s plans and timelines for the clinical development and regulatory review of EQRx’s product candidates both in and outside the U.S., and the therapeutic potential and clinical benefits and tolerability of EQRx’s product candidates. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to changes in the competitive and highly regulated industries in which EQRx operates, the timing and outcome of EQRx’s planned interactions with regulatory authorities, changes in laws and regulations affecting EQRx’s business, delay of any current and future clinical trials or the development of aumolertinib, sugemalimab or EQRx’s other drug candidates, the risk that the results of prior clinical trials may not be predictive of future results in connection with future clinical trials, EQRx’s ability to successfully demonstrate the safety and efficacy of its drug candidates, the timing and outcome of EQRx’s planned interactions with regulatory authorities; obtaining, maintaining and protecting its intellectual property, EQRx’s relationships with its existing and future collaboration partners, risks associated with EQRx’s ability to otherwise implement its business plans, including risks associated with its growth strategy, obtaining regulatory approvals, and other risks associated with its plans to create a new kind of pharmaceutical company, the risk of downturns and a changing regulatory landscape in the highly competitive healthcare and biopharmaceutical industries, the size and growth of the markets in which EQRx operates and its ability to offer innovative medicines at reduced prices, and EQRx’s ability to operate as a public company. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section in EQRx’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as well as any other filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and EQRx assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Investors and others should note that we communicate with our investors and the public using our website www.eqrx.com, including, but not limited to, company disclosures, investor presentations and FAQs, SEC filings, press releases, public conference call transcripts and webcast transcripts. The information that we post on our website could be deemed to be material information. As a result, we encourage investors, the media and others interested parties to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing with the SEC.

EQRx Contacts:

Media:

Dan Budwick
1AB
dan@1abmedia.com

Adjoa Kyerematen
Media Relations Director
media@EQRx.com

Investors:
investors@EQRx.com

[1] *EQRx and CStone Pharmaceuticals have partnered on the global development of sugemalimab. This presentation will be shared by CStone and its collaborators.*

[2] *EQRx and Hansoh Pharmaceuticals have partnered on the global development of aumolertinib. This presentation will be shared by Hansoh Pharmaceuticals and its collaborators.*